Laser Acupuncture for Fatigue in Hemodialysis Patients
NCT: NCT07538310 · NOT_YET_RECRUITING
Brief Summary
The goal of this clinical trial is to learn if laser acupuncture (low-level laser therapy) works to treat fatigue and improve quality of life in adults with end-stage renal disease (ESRD) undergoing hemodialysis. It will also learn about how laser acupuncture affects blood circulation and autonomic nervous system balance. The main questions it aims to answer are: 1. Does laser acupuncture reduce the severity of fatigue and its interference with daily life? 2. Can laser acupuncture improve related symptoms such as insomnia, poor appetite, and skin itching? 3. How does laser acupuncture affect objective markers like microcirculation and heart rate variability? Researchers will compare laser acupuncture to a sham treatment (a look-alike procedure using a device that does not emit a laser) to see if laser acupuncture works to treat fatigue. Participants will: 1. Receive laser acupuncture or a sham treatment during their regular hemodialysis sessions 3 times a week for 4 weeks. 2. Have their fatigue and life quality assessed through questionnaires on the first day, at 4 weeks, and at 8 weeks. 3. Undergo non-invasive tests to measure microcirculation, heart rate variability, and pulse waves, and have photos of their tongue taken for Chinese medicine assessment.
Frequently Asked Questions
What is Laser Acupuncture for Fatigue in Hemodialysis Patients?
Laser Acupuncture for Fatigue in Hemodialysis Patients is a clinical trial registered under NCT07538310. Current status: NOT_YET_RECRUITING.
What is the status of NCT07538310?
The current status of NCT07538310 (Laser Acupuncture for Fatigue in Hemodialysis Patients) is: NOT_YET_RECRUITING.
When did Laser Acupuncture for Fatigue in Hemodialysis Patients start?
Laser Acupuncture for Fatigue in Hemodialysis Patients started on 2026-04-08.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.